Wire · operational-macro
Prime Medicine Gets FDA Green Light for Gene Editing Study
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 September 2026 · Fusion42 review
Prime Medicine received FDA clearance for its Investigational New Drug application to begin clinical studies in the U.S. for PM647, a gene editing therapy targeting Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder affecting lung and liver function mainly in the US and Europe.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 26 Sep 2026 and 28 Sep 2026.
◆ ◆ The Wire takeaway
FDA approval for Prime Medicine's gene editing trial opens the US AATD treatment market to novel genetic therapies. You can explore new partnerships or clinical development opportunities in this underserved rare disease segment.
◆ Coverage
2 sources · first reported 26 Sep 2026 · latest 28 Sep 2026
◆ Related on Wire
◆ Topics